Literature DB >> 12602511

Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion.

Franco Del Piccolo1, David Sacerdoti, Piero Amodio, GianCarlo Bombonato, Massimo Bolognesi, Daniela Mapelli, Angelo Gatta.   

Abstract

The role of portal-systemic shunting and portal liver hypoperfusion in the pathophysiology of central nervous system dysfunction of cirrhosis is not yet well defined. It is well known that one of the most important collateral vessels (CV) is a patent paraumbilical vein (PUV) but there is controversy regarding its clinical significance. We have evaluated the relationships between neuropsychological and EEG alterations, ammonia plasma level (NH4), hepatic function, and portal hemodynamics (Doppler Ultrasound) in 95 cirrhotic patients. Patency, diameter, or flow of PUV or the presence of other CV were not related to an increased prevalence of neuropsychological or EEG abnormalities. Patients with effective portal flow (EPF = portal flow - PUV flow) lower than 692 mL/min (median) had a significantly higher risk of failing the neuropsychological test, or of having an altered EEG. Low EPF and prothrombin time (<50%), and high NH4 (> or = 51 micromol/L) were independent predictors of an abnormal EEG. Considering both low EPF and the numerosity of CV, only low EPF was found to explain EEG alterations. In conclusion, portal liver hypoperfusion and decreased liver function were associated with an increased risk of central nervous system dysfunction in cirrhotic patients, whereas PUV patency per se was not.

Entities:  

Mesh:

Year:  2002        PMID: 12602511     DOI: 10.1023/a:1021914003218

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  38 in total

1.  Blood ammonia levels in hepatic cirrhosis: their control by the oral administration of neomycin.

Authors:  C J FISHER; W W FALOON
Journal:  N Engl J Med       Date:  1957-05-30       Impact factor: 91.245

2.  Ammonium tolerance in liver disease: observations based on catheterization of the hepatic veins.

Authors:  L P WHITE; E A PHEAR; W H SUMMERSKILL; S SHERLOCK
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

3.  Preoperative liver function tests correlated with encephalopathy after porta-caval anastomosis.

Authors:  T Kardel; K Ramsöe; S Nörby Rasmussen
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

4.  Direction of splenic venous flow assessed by pulsed Doppler flowmetry in patients with a large splenorenal shunt. Relation to spontaneous hepatic encephalopathy.

Authors:  K Ohnishi; M Saito; S Sato; T Nakayama; M Takashi; S Iida; F Nomura; H Koen; K Okuda
Journal:  Gastroenterology       Date:  1985-07       Impact factor: 22.682

5.  Selective and total shunts in the treatment of bleeding varices. A randomized controlled trial.

Authors:  J T Galambos; W D Warren; D Rudman; R B Smith; A A Salam
Journal:  N Engl J Med       Date:  1976-11-11       Impact factor: 91.245

6.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

7.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

9.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

Authors:  O Riggio; M Merlli; G Pedretti; R Servi; P Meddi; R Lionetti; P Rossi; M Bezzi; F Salvatori; U Ugolotti; F Fiaccadori; L Capocaccia
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

10.  Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.

Authors:  O Riggio; G Balducci; F Ariosto; M Merli; U Pieche; G Pinto; S Tremiterra; V Ziparo; L Capocaccia
Journal:  Dig Dis Sci       Date:  1989-06       Impact factor: 3.199

View more
  3 in total

Review 1.  Portosystemic shunt syndrome and endovascular management of hepatic encephalopathy.

Authors:  Wael E Saad
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

2.  Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy.

Authors:  Marco Senzolo; Lisa Zarantonello; Chiara Formentin; Costanza Orlando; Raffaello Beltrame; Anna Vuerich; Paolo Angeli; Patrizia Burra; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2019-09-10       Impact factor: 3.584

3.  What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?

Authors:  Giovanni Tarantino; Vincenzo Citro; Paolo Conca; Antonio Riccio; Marianna Tarantino; Domenico Capone; Michele Cirillo; Roberto Lobello; Vittorio Iaccarino
Journal:  BMC Gastroenterol       Date:  2009-11-24       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.